Real World Utilization of Stiripentol (STP) by United States (US) Prescribers: A 3-Year Analysis Update
Abstract number :
2.452
Submission category :
7. Anti-seizure Medications / 7E. Other
Year :
2025
Submission ID :
1364
Source :
www.aesnet.org
Presentation date :
12/7/2025 12:00:00 AM
Published date :
Authors :
Presenting Author: Andrea Calvert, PharmD, BCPPS – Biocodex
Kelly Gwin, PharmD – Biocodex
Carly Katterman, PharmD – Biocodex
Veanna Fong, N/A – Biocodex
Fabiola Garcia, N/A – Biocodex
Carla Schad, MD – Biocodex
Rationale: Dravet syndrome (DS) is characterized by drug-resistant seizures, requiring polytherapy and individualized dosing for adequate seizure control. Despite rational polytherapy recommendations and availability of DS-approved antiseizure medications (ASMs), stiripentol (STP), cannabidiol (CBD), and fenfluramine (FFA), integration into treatment regimens remains limited1. To expand upon our previous real-world analysis2, this review was extended through 2025 to evaluate STP dosing patterns, age-based variations, and concomitant ASMs, further characterizing US prescribing practices.
Methods: A retrospective analysis was performed using data of new US patients (pts) prescribed STP from August 2022–April 2025. Data collected included age, weight, diagnosis code, STP dosage, months on therapy, and concomitant ASMs at initiation. Prescribing patterns were evaluated for frequency of DS-specific ASM use, prevalence of polytherapy, and dosing trends of STP dependent on age/months on therapy. Data were compared with previous analyses to identify evolving trends2.
Results: Data were analyzed for pts <
Anti-seizure Medications